Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

ANDA Reformulations Should Not Result In Loss Of 180-Day Exclusivity - Andrx

Oct 25 1999

• By The Pink Sheet

Related Content

Purepac Challenges Andrx Cardia XT Exclusivity On Reformulation Grounds

Aug 16 1999

More from Archive

More from Pink Sheet

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window